1. Home
  2. CNTN vs NYXH Comparison

CNTN vs NYXH Comparison

Compare CNTN & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Canton Strategic Holdings Inc. Common Stock

CNTN

Canton Strategic Holdings Inc. Common Stock

HOLD

Current Price

$1.88

Market Cap

178.5M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

BUY

Current Price

$0.85

Market Cap

137.5M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
CNTN
NYXH
Founded
2017
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.5M
137.5M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
CNTN
NYXH
Price
$1.88
$0.85
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $4.20
AVG Volume (30 Days)
★ 735.7K
217.2K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 88.10
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$275.91
Revenue Next Year
N/A
$93.27
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.66
$0.80
52 Week High
$5.27
$5.92

Technical Indicators

Market Signals
Indicator
CNTN
NYXH
Relative Strength Index (RSI) 42.22 23.47
Support Level $1.75 N/A
Resistance Level $2.40 $1.69
Average True Range (ATR) 0.14 0.05
MACD -0.02 -0.05
Stochastic Oscillator 27.07 5.85

Price Performance

Historical Comparison
CNTN
NYXH

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: